Biotech news
Asia
Even if India moves towards a patent-unfriendly environment for green technologies, the pro-patent and pro-environment lobbies can coexist and meet their respective goals, argue Swarup Kumar and Jitesh Kumar of Remfry & Sagar. 11 August 2016
Americas
Amgen has entered into a global agreement with Advaxis, allowing for the development and commercialisation of ADXS-NEO, a preclinical cancer immunotherapy treatment. 10 August 2016
Americas
The US and China take very different approaches to the patentability of a range of inventions in the life sciences field, as Yu Guo of China Patent Agent reports. 9 August 2016
Asia-Pacific
A new fund dedicated to accelerate the development and commercialisation of Australian biomedical discoveries has officially launched. 5 August 2016
Americas
Fustibal, a targeted therapeutics biotechnology start-up, has filed an inter partes review petition challenging a patent owned by German pharmaceutical company Bayer. 4 August 2016
Americas
Editas Medicine, a US genome-editing company, announced yesterday that it has entered into an exclusive licensing agreement with Massachusetts General Hospital to access CRISPR technology. 4 August 2016
Americas
Inter-partes reviews (IPRs) can be a powerful weapon against patents listed in the Orange Book. However, IPR practice favours a petitioner who has carefully thought about the issues and crafted the best strategy, says Mark Remus of Brinks Gilson & Lione. 4 August 2016
Americas
Pfizer has acquired Bamboo Therapeutics, a biotechnology company based in North Carolina. 3 August 2016
Americas
The US Court of Appeals for the Federal Circuit yesterday affirmed a district court’s order to deny arbitration in a patent infringement case between Illumina and Ariosa Diagnostics. 27 July 2016
Americas
Law firm Cooley announced yesterday that it is expanding its patent counselling and prosecution practice with the addition of Mika Reiner Mayer’s team from law firm Morrison Foerster. 26 July 2016